Marker Therapeutics (MRKR) AI Stock Analysis

• Market Cap: $30.01M
• Dividend Yield: N/A
• Average Volume (3M): 449.76K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.60
• Revenue Growth: -12.99%
• EPS Growth: -13.67%
• Country: US
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.12
• Shares Outstanding: 16,673,126
• 10 Day Avg. Volume: 493,497
• 30 Day Avg. Volume: 449,763
• PEG Ratio: 0.07
• Price to Book (P/B): 1.50
• Price to Sales (P/S): 4.24
• P/FCF Ratio: -2.56
• Enterprise Value/Market Cap: >-0.01
• Enterprise Value/Revenue: -0.04
• Enterprise Value/Gross Profit: 0.03
• Enterprise Value/Ebitda: 0.02
• 1Y Price Target: $9.00
• Price Target Upside: 452.15% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -1.23
• Revenue Forecast (FY): $2.68M

• Rating: 53 Neutral
• Price Target: $2.00 ▲(22.70% Upside)

The score is held back primarily by weak financial performance (declining revenue, very negative margins, and ongoing cash burn), despite the benefit of zero debt. Technical indicators are a key support, showing strong momentum with price above major moving averages and a positive MACD. Valuation contributes modestly negatively because the negative P/E reflects continued losses and there is no dividend yield data.

Positive Factors

Balance Sheet / Leverage

Zero reported debt materially reduces solvency and refinancing risk for a clinical-stage biotech. This preserves strategic optionality to fund trials, pursue partnerships or raise equity on better terms, supporting program continuity over the next several quarters.

Improving Cash Flow Trend

Although cash flow is negative, the 36% improvement in free cash flow and close tracking to net income indicate better cash discipline and operational alignment. This trend, if sustained, lowers future funding needs and improves runway for clinical programs.

Platform & Therapeutic Focus

A multi-antigen T‑cell platform addresses antigen escape and aims for broader tumor applicability. As immuno-oncology and cell therapies remain structural growth areas, a differentiated MultiTAA approach provides durable scientific relevance and potential partnership interest.

Negative Factors

Weak Profitability & Revenue Trend

Declining revenue combined with deeply negative margins signal the business is far from breakeven. Persistent operating losses erode equity value, require ongoing external funding, and complicate long-term planning for scaling clinical programs or commercialization.

Persistent Cash Burn

Sustained negative operating and free cash flow at material levels constrains runway and forces recurring financing or dilutive capital raises. That pressure can slow R&D momentum, delay trials, and increase dependency on partners or milestone-based funding.

Limited Operating Scale

A very small headcount raises execution and scalability risk for complex clinical programs. Reliance on outsourcing or partners increases coordination, cost and timeline risks, and may limit the firm's ability to rapidly expand trials or build in-house capabilities for commercialization.

Marker Therapeutics Business Overview & Revenue Model

Company Description

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

How the Company Makes Money

Marker Therapeutics generates revenue primarily through partnerships, collaborations, and licensing agreements with other biotechnology and pharmaceutical companies. These collaborations often involve upfront payments, milestone payments based on the achievement of specific clinical or regulatory objectives, and royalties on future product sales. Additionally, the company may receive funding from grants and research agreements to support the development of its therapeutic candidates. As a clinical-stage company, Marker Therapeutics does not yet generate revenue from product sales, as its products are still undergoing clinical trials and have not yet received regulatory approval for commercialization.

Marker Therapeutics Financial Statement Overview

Summary

Overall financial quality is weak: TTM revenue declined (-12.9%), margins are deeply negative (net margin ~-305%), and the company is far from breakeven. The main offset is a clean balance sheet with zero debt, but persistent losses and cash burn dominate the outlook.

Income Statement

TTM (Trailing-Twelve-Months) revenue declined (-12.9%), and profitability remains weak with deeply negative gross profit and operating results (net margin ~-305%). While losses have generally narrowed versus the extreme 2020–2021 period, the business is still far from breakeven and shows ongoing pressure on unit economics.

Balance Sheet

The balance sheet is relatively clean from a leverage standpoint: total debt is 0 in 2023–TTM (Trailing-Twelve-Months) and debt-to-equity is 0, reducing solvency risk. Offsetting that strength, equity returns remain meaningfully negative (TTM return on equity ~-92%), indicating continued value erosion from ongoing losses despite a stable capital structure.

Cash Flow

Cash generation remains a key weakness: TTM (Trailing-Twelve-Months) operating cash flow and free cash flow are both about -$14.8M, reflecting continued cash burn. A positive note is that free cash flow burn improved versus the prior year (TTM free cash flow growth +36%), and free cash flow roughly tracks net income (near 1x), but absolute cash outflows are still large and persistent.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.69M	6.59M	3.31M	3.51M	1.24M	466.79K
Gross Profit	-7.70M	-6.88M	-7.11M	-8.45M	-1.92M	-18.41M
EBITDA	-10.12M	-11.12M	-11.79M	-17.00M	-38.72M	-27.63M
Net Income	-14.30M	-10.73M	-8.24M	-29.93M	-41.88M	-28.71M
Balance Sheet
Total Assets	21.73M	22.02M	17.13M	34.42M	68.14M	45.61M
Cash, Cash Equivalents and Short-Term Investments	17.59M	19.19M	15.11M	11.78M	42.35M	21.35M
Total Debt	0.00	0.00	0.00	7.62M	11.87M	12.26M
Total Liabilities	3.35M	3.46M	3.07M	14.82M	24.15M	18.27M
Stockholders Equity	18.39M	18.56M	14.05M	19.60M	43.99M	27.34M
Cash Flow
Free Cash Flow	-14.82M	-10.91M	-16.44M	-26.97M	-30.41M	-29.29M
Operating Cash Flow	-14.82M	-10.91M	-16.44M	-26.97M	-27.28M	-20.03M
Investing Cash Flow	0.00	0.00	18.66M	-4.95M	-3.13M	-9.25M
Financing Cash Flow	24.76M	14.99M	1.11M	202.13K	52.56M	6.74M

Marker Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.63
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRKR, the sentiment is Neutral. The current price of 1.63 is below the 20-day moving average (MA) of 1.85, above the 50-day MA of 1.50, and above the 200-day MA of 1.28, indicating a neutral trend. The MACD of 0.11 indicates Positive momentum. The RSI at 46.09 is Neutral, neither overbought nor oversold. The STOCH value of 21.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MRKR.

Marker Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IBIO	55 Neutral	$51.27M	-1.60	-54.50%	―	185.71%	79.03%
MRKR	53 Neutral	$30.01M	-1.33	-110.67%	―	-12.99%	-13.67%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ADXN	51 Neutral	$10.31M	-0.92	-71.27%	―	-72.15%	-223.62%
MBRX	45 Neutral	$13.92M	-0.08	―	―	―	79.31%
ABVC	44 Neutral	$50.06M	-9.09	-40.32%	―	56.52%	75.22%
ALLR	42 Neutral	$19.27M	-0.68	-122.61%	―	―	99.82%